AvantCap AG High yields and capping efficiencies
Enhanced translation
ExploCap Delivers high IVT yields and capping efficiencies
AvantCap Q1 Delivers high yields and capping efficiencies across a wide range of IVT conditions
AvantCap Q2 Delivers Cap 2 modification with high yields and capping efficiencies across a wide range of IVT conditions

Jacek Jemielity Chief Executive Officer
Joanna Kowalska Chief Technology Officer
Jakub Gołąb Chief Scientific Officer
Mateusz Gołąb Board Member, Chief Financial Officer
Tomasz Piec Board Member
Dominika Nowis Director of Biology
Marek Baranowski Director of Research and Quality Development
Piotr Stępniak Director of Business Development

News

March 3, 2025

ExploRNA @ RNA Leaders Europe Congress in Basel Read more

February 28, 2025

Prof. Jacek Jemielity invited to give a seminar at the RNA Therapeutics Institute UMass Chan Medical School Read more

October 2, 2024

ExploRNA at the Polish Embassy in Tokyo and BioJapan 2024 in Yokohama! Read more

September 3, 2024

Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines Read more

August 22, 2024

Meet ExploRNA’s CEO at PHASE2024 in Warsaw Read more

March 8, 2024

AvantCap publication in JACS Read more

February 28, 2024

ExploRNA joins the Alliance for mRNA Medicines Read more

August 16, 2023

ExploRNA at PHASE2023 Read more